-
Mashup Score: 0CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19 - 1 year(s) ago
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is…
Categories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19 - 1 year(s) ago
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These novel therapies targeting disease specific antigens such as CD19 in lymphoma and B cell maturation antigen in multiple myeloma have been shown to be efficacious and reasonably well tolerated, especially when compared to conventional chemotherapies….
Categories: Hem/Oncs, Latest HeadlinesTweet
Very nice review! 👏🏽👏🏽 CAR-T for B-cell lymphomas with a focus on targets beyond CD19 #CARTcell #lymsm #TcellRx #celltherapy https://t.co/ecbcpXHbIQ https://t.co/vXMj5ebQwX